Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Orthex Publishes Update to Financial Calendar

Orthex Publishes Update to Financial Calendar

BitgetBitget2026/11/05 06:32
  • Orthex will publish its 2026 financial statements release on March 3, 2027, at approximately 9 a.m. EET.
  • Interim reports are scheduled for May 5, 2027, covering January-March, and Nov. 4, 2027, covering January-September.
  • The January-June 2027 half-year financial report is due Aug. 18, 2027, at approximately 9 a.m. EEST.
  • The 2026 Annual and Sustainability Report, including the board report and financial statements, will appear online by week 11 of March 2027.
  • The annual general meeting is planned for April 8, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthex Oyj published the original content used to generate this news brief via Cision (Ref. ID: 202611050130BITN____UKPR__EN_20261104-BIT-4782-0) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss